Emily Ford is an Infectious Disease physician affiliated with University of Washington. OpenAlex indexes 73 publications with 1,565 citations (h-index 19).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1959 NE Pacific St
Seattle, WA 981950001
Telephone
206-288-1000Provider last certified this registry record 23 Sept 2021.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Astellas Pharma US IncProgram year20241 payment
- Abbott LaboratoriesProgram year20231 payment
- GENZYME CORPORATIONProgram year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
27.1%Statin16.6%Rosuvastatin Calcium63%Atorvastatin Calcium37%Part D<11 patientsACE inhibitor10.5%Lisinopril100%Part D<11 patientsNervous system
25.8%SSRI8.3%Trazodone Hcl100%Part D<11 patientsAzaspirodecanedione derivatives7%Buspirone Hcl100%Part D<11 patients+ 2 more classes in this area
Anti-infectives
25.8%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor11.8%Dovato56%Juluca44%Part D<11 patientsHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor8.7%Triumeq100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2020–2026 per NIH RePORTER. The latest:
- Immune signatures of CMV disease risk after orthotopic liver transplant
University of Washington
FY2026$733,731R01AI189491 - Immune signatures of CMV disease risk after orthotopic liver transplant
University of Washington
FY2025$832,910R01AI189491 - HSV-2 specificity and phenotyping of tissue-based T cells in genital skin biopsies of HSV-2 reactivation
University of Washington
FY2024$189,432K08AI148588
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Neal Futran, MD, DMD
University of Washington
Elizabeth Swisher
University of Washington
David Tirschwell
University of Washington
Elaine Peskind, MD
University of Washington
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”